Akums demonstrates clinical versatility of Lacosamide in epilepsy care
Clinical evidence has consistently highlighted lacosamide’s efficacy and safety.
Clinical evidence has consistently highlighted lacosamide’s efficacy and safety.
Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada
Keytruda Qlex is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
The inspection concluded with zero form 483 observations
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
Includes new $1.2 billion investment in manufacturing facilities, AI and advanced digital technologies, creating hundreds of highly skilled U.S. jobs
This marks the first of four new U.S. manufacturing sites that Lilly plans to announce this year
Subscribe To Our Newsletter & Stay Updated